What did @lovelyladynotes actually say?
In one month on a compounded GLP-1 plan, she says she lost 11 pounds, reduced inflammation, gained energy, and experienced "little to none" side effects. She described those benefits, including energy and reduced inflammation, as "side effects" themselves. She also promoted a personalized quiz-based prescribing process and offered a discount code.
To her credit, she was transparent about the affiliate relationship by using a discount code and the video carries #ivyaffiliate and #ivypartner tags. That is more disclosure than most sponsored health content on TikTok. But the claims themselves deserve a closer look, because several of them range from oversimplified to genuinely unsupported by the current evidence.
Does the science back this up?
Some of it, yes. The weight loss and reduced food cravings she describes are well-documented. The inflammation and energy claims are where things get murky, and the "little to none" side effect framing contradicts what clinical trial data actually shows.
On weight loss: semaglutide and tirzepatide produce meaningful early weight loss in clinical settings. The SURMOUNT-1 trial (Jastreboff et al., 2022, New England Journal of Medicine) showed tirzepatide producing significant weight reduction, with effects beginning in early weeks. Eleven pounds in 30 days is on the higher end but not impossible, especially with water weight and reduced food intake combined.
On inflammation: GLP-1 receptors are expressed in immune cells, and some research suggests anti-inflammatory effects. A 2023 review by Muskiet et al. in Cardiovascular Diabetology noted GLP-1 receptor agonists may reduce systemic inflammatory markers. But "inflammation down" as a casually stated side effect after one month, without any lab work cited, is speculative at best.
On energy: there is no strong clinical evidence that GLP-1 medications directly cause increased energy. Feeling better from eating less processed food and losing weight can improve energy indirectly. That is not the same as the drug boosting energy.
What did they get wrong (or right)?
The biggest problem is her characterization of side effects. Saying she had "little to none" and framing higher energy and weight loss as the side effects is misleading. Clinical trial data tells a different story.
In the SCALE trial (Pi-Sunyer et al., 2015, New England Journal of Medicine) for liraglutide, nausea affected over 30% of participants. For semaglutide in STEP 1 (Wilding et al., 2021, NEJM), nausea affected 44% of participants and gastrointestinal events were the most common reason for discontinuation. Some people do tolerate GLP-1 medications very well, and her experience may be genuine. But presenting minimal side effects as the expected norm for a first-time viewer is genuinely irresponsible.
She also says compounded GLP-1 is "not one size fits all," implying personalization is a unique feature of compounded formulations. This framing is worth scrutinizing. FDA-approved GLP-1 medications also involve clinical assessment and dose titration. Compounded versions are not FDA-approved for safety and efficacy, and FormBlends and any responsible telehealth platform should be clear that compounded semaglutide or tirzepatide is not equivalent to a brand-name drug in terms of regulatory review.
What she got right: GLP-1 medications do reduce food cravings, often described as quieting "food noise," and this is supported by research. A 2022 study by Blundell et al. in Diabetes, Obesity and Metabolism confirmed semaglutide significantly reduced appetite and food cravings.
What should you actually know?
GLP-1 medications are legitimate, well-studied tools for weight management. But they are also prescription medications with real side effect profiles, real contraindications, and real questions around compounded versions specifically.
First, the side effect picture: nausea, vomiting, diarrhea, and constipation are among the most commonly reported effects, particularly in the first few weeks. One person's mild headache is another person's reason to stop treatment. Hearing only positive experiences from creators with affiliate codes is a skewed sample.
Second, compounded GLP-1 products exist in a regulatory gray area. The FDA has warned consumers about the risks of compounded semaglutide, including dosing inconsistencies and quality control concerns. Compounded formulations are not FDA-approved and should not be assumed equivalent to brand-name products like Wegovy or Zepbound.
Third, a quiz-based intake process is a starting point, not a full medical evaluation. Legitimate telehealth prescribing should include a review of your full medical history, contraindications such as personal or family history of medullary thyroid carcinoma, and informed consent about off-label or compounded use.
If you are considering a GLP-1 medication, talk to a licensed provider who can review your complete health history, not just a quiz result filtered through an affiliate funnel.